Načítá se...
New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
Rearrangements in ALK gene and EML4 gene were first described in 2007. This genomic aberration is found in about 2%–8% of non-small-cell lung cancer (NSCLC) patients. Crizotinib was the first ALK tyrosine kinase inhibitor licensed for the treatment of metastatic ALK-positive NSCLC based on a randomi...
Uloženo v:
| Vydáno v: | Ther Clin Risk Manag |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863587/ https://ncbi.nlm.nih.gov/pubmed/27217763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S87876 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|